Castle Biosciences (CSTL) News Today $27.53 +0.44 (+1.62%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells $265,375.76 in StockDecember 20 at 8:49 AM | insidertrades.comInsider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 9,364 Shares of StockCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 9,364 shares of Castle Biosciences stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $28.34, for a total transaction of $265,375.76. Following the transaction, the insider now directly owns 84,762 shares in the company, valued at $2,402,155.08. The trade was a 9.95 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.December 19 at 7:24 PM | marketbeat.comShort Interest in Castle Biosciences, Inc. (NASDAQ:CSTL) Expands By 7.6%Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) was the recipient of a significant increase in short interest during the month of November. As of November 30th, there was short interest totalling 1,840,000 shares, an increase of 7.6% from the November 15th total of 1,710,000 shares. Based on an average trading volume of 390,900 shares, the days-to-cover ratio is currently 4.7 days.December 17, 2024 | marketbeat.comIndependent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences’ DecisionDx®-Melanoma Test, Contributing to ...December 12, 2024 | businesswire.comCharles Schwab Investment Management Inc. Purchases 39,417 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)Charles Schwab Investment Management Inc. boosted its position in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 16.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 274,761 shares of the company'sDecember 11, 2024 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Insider Derek J. Maetzold Sells 1,972 SharesDecember 10, 2024 | insidertrades.comPoint72 Asset Management L.P. Purchases 445,415 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)Point72 Asset Management L.P. increased its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 828.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 499,192 shares of the company's stock after bDecember 7, 2024 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Shares Sold by Jacobs Levy Equity Management Inc.Jacobs Levy Equity Management Inc. decreased its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 4.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 496,521 shares of the comDecember 5, 2024 | marketbeat.comParkman Healthcare Partners LLC Raises Stake in Castle Biosciences, Inc. (NASDAQ:CSTL)Parkman Healthcare Partners LLC increased its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 6.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 296,071 shares of the company's stock after acquiring aDecember 4, 2024 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of "Buy" by AnalystsShares of Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) have been given a consensus recommendation of "Buy" by the eight ratings firms that are covering the company, Marketbeat reports. Eight analysts have rated the stock with a buy recommendation. The average 12-month target price amonDecember 3, 2024 | marketbeat.comCastle Biosciences Inc.December 3, 2024 | wsj.comBellevue Group AG Grows Stake in Castle Biosciences, Inc. (NASDAQ:CSTL)Bellevue Group AG raised its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 3.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,262,030 shares of the company's stocDecember 1, 2024 | marketbeat.comBraidwell LP Has $9.47 Million Stake in Castle Biosciences, Inc. (NASDAQ:CSTL)Braidwell LP reduced its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 20.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 331,986 shares of the company's stock after selling 84,114 shares duringNovember 29, 2024 | marketbeat.com43,894 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Acquired by Dynamic Technology Lab Private LtdDynamic Technology Lab Private Ltd bought a new stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 43,894 shares of the company's stock, vaNovember 27, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Boosts Position in Castle Biosciences, Inc. (NASDAQ:CSTL)Connor Clark & Lunn Investment Management Ltd. raised its stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 147.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 165,458 shares of the company'sNovember 24, 2024 | marketbeat.comCastle Biosciences to Present at the Piper Sandler 36th Annual Healthcare ConferenceNovember 20, 2024 | finance.yahoo.comFrank Stokes Sells 6,923 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) StockNovember 20, 2024 | insidertrades.comCastle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive YearNovember 19, 2024 | finance.yahoo.comCastle Biosciences (NASDAQ:CSTL) Shares Down 7.3% After Insider SellingCastle Biosciences (NASDAQ:CSTL) Shares Down 7.3% After Insider SellingNovember 15, 2024 | marketbeat.comInsider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 1,972 Shares of StockNovember 15, 2024 | insidertrades.comGSA Capital Partners LLP Takes Position in Castle Biosciences, Inc. (NASDAQ:CSTL)GSA Capital Partners LLP acquired a new position in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 51,827 shares of the company'sNovember 14, 2024 | marketbeat.comCastle Biosciences' (NASDAQ:CSTL) Performance Is Even Better Than Its Earnings SuggestNovember 12, 2024 | finance.yahoo.comCastle Biosciences, Inc. (NASDAQ:CSTL) Shares Bought by Lisanti Capital Growth LLCLisanti Capital Growth LLC lifted its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 60.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 154,710 shares of the company's stock after buying an additNovember 11, 2024 | marketbeat.comPrincipal Financial Group Inc. Purchases 40,377 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)Principal Financial Group Inc. lifted its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 2.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,538,520 shares of the companyNovember 11, 2024 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells $124,708.92 in StockNovember 8, 2024 | insidertrades.comKornitzer Capital Management Inc. KS Reduces Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL)Kornitzer Capital Management Inc. KS lowered its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 25.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 407,238 shares of the cNovember 7, 2024 | marketbeat.comResearch Analysts Offer Predictions for CSTL FY2024 EarningsCastle Biosciences, Inc. (NASDAQ:CSTL - Free Report) - Research analysts at Leerink Partnrs increased their FY2024 EPS estimates for shares of Castle Biosciences in a research note issued on Monday, November 4th. Leerink Partnrs analyst P. Souda now anticipates that the company will earn $0.32 peNovember 7, 2024 | marketbeat.comCastle Biosciences price target raised to $44 from $37 at ScotiabankNovember 6, 2024 | markets.businessinsider.comScotiabank Sticks to Its Buy Rating for Castle Biosciences (CSTL)November 6, 2024 | markets.businessinsider.comCastle Biosciences Faces Financial Strain Amid 2024 Loan Covenant RestrictionsNovember 6, 2024 | markets.businessinsider.comCastle Biosciences price target raised to $36 from $28 at KeyBancNovember 6, 2024 | finance.yahoo.comCastle Biosciences price target raised to $39 from $37 at BairdNovember 6, 2024 | finance.yahoo.comCastle Biosciences Reports Third Quarter 2024 ResultsNovember 6, 2024 | finance.yahoo.comCastle Biosciences, Inc. (NASDAQ:CSTL) Q3 2024 Earnings Call TranscriptNovember 6, 2024 | msn.comCastle Biosciences Inc (CSTL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...November 6, 2024 | finance.yahoo.comCastle Biosciences price target raised to $45 from $40 at BTIGNovember 6, 2024 | markets.businessinsider.comCastle Biosciences (CSTL) Gets a Buy from Lake StreetNovember 6, 2024 | markets.businessinsider.comCastle Biosciences (NASDAQ:CSTL) Posts Quarterly Earnings Results, Beats Expectations By $0.14 EPSCastle Biosciences (NASDAQ:CSTL - Get Free Report) posted its quarterly earnings data on Monday. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.14. Castle Biosciences had a negative net margin of 1.08% and a negative return on equity of 0.77%. The firm had revenue of $85.78 million for the quarter, compared to analysts' expectations of $78.55 million. During the same quarter last year, the company posted ($0.26) EPS.November 5, 2024 | marketbeat.comCastle Biosciences (NASDAQ:CSTL) Reaches New 52-Week High After Earnings BeatCastle Biosciences (NASDAQ:CSTL) Reaches New 12-Month High on Better-Than-Expected EarningsNovember 5, 2024 | marketbeat.comCastle Biosciences (NASDAQ:CSTL) Given New $39.00 Price Target at Robert W. BairdRobert W. Baird boosted their price objective on Castle Biosciences from $37.00 to $39.00 and gave the stock an "outperform" rating in a research note on Tuesday.November 5, 2024 | marketbeat.comCastle Biosciences, Inc. (CSTL) Q3 2024 Earnings Call TranscriptNovember 4, 2024 | seekingalpha.comCastle Biosciences, Inc. 2024 Q3 - Results - Earnings Call PresentationNovember 4, 2024 | seekingalpha.comHarbor Capital Advisors Inc. Acquires 15,200 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)Harbor Capital Advisors Inc. increased its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 11.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 153,907 shares of the company's stock after puNovember 4, 2024 | marketbeat.comCastle Biosciences Inc (CSTL) Q3 2024 Earnings Report Preview: What To ExpectNovember 3, 2024 | finance.yahoo.comCastle Biosciences (NASDAQ:CSTL) Stock Price Down 3.8% - Time to Sell?Castle Biosciences (NASDAQ:CSTL) Shares Down 3.8% - Should You Sell?November 1, 2024 | marketbeat.comCastle Biosciences to present new TissueCypher data at ACG 2024October 30, 2024 | markets.businessinsider.comCastle Biosciences price target raised to $42 from $35 at CanaccordOctober 29, 2024 | markets.businessinsider.comCastle Biosciences (NASDAQ:CSTL) PT Raised to $42.00 at Canaccord Genuity GroupCanaccord Genuity Group upped their price target on shares of Castle Biosciences from $35.00 to $42.00 and gave the company a "buy" rating in a research note on Tuesday.October 29, 2024 | marketbeat.comSG Americas Securities LLC Sells 19,330 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)SG Americas Securities LLC lowered its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 71.6% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,659 shares of theOctober 23, 2024 | marketbeat.comCastle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b TumorsOctober 20, 2024 | businesswire.com Get Castle Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Buy this coin BEFORE Inauguration Day … (Ad)Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office. This could be his favorite coin. CSTL Media Mentions By Week CSTL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CSTL News Sentiment▼0.940.60▲Average Medical News Sentiment CSTL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CSTL Articles This Week▼44▲CSTL Articles Average Week Get Castle Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LifeStance Health Group News Surgery Partners News Concentra Group Holdings Parent News Privia Health Group News Ardent Health Partners News Addus HomeCare News PACS Group News GeneDx News National HealthCare News Teladoc Health News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CSTL) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Castle Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Castle Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
